SHERPA

5 Nov, 2018

NeoantigenID

NeoantigenID™ Comprehensive Identification of Putative Neoantigens Neoantigens are mutated peptides that are expressed by tumor cells, but not by normal tissue. As a result, they can be recognized as foreign antigens by cells of the immune system — making them promising targets for personalized cancer immunotherapies such as vaccines [...]

1 Oct, 2017

Genomics Solutions for Neoantigen Based Cancer Therapies

Genomics Solutions for Neoantigen Based Cancer Therapies High quality, comprehensive genomic data and analytics for personalized cancer therapy development Enabling Truly Personalized Neoantigen Based Cancer Therapies The first step of developing personalized cancer therapeutics is the identification of patient-specific neoantigens. With ImmunoID NeXT™, our partners can utilize our proprietary [...]

Go to Top